Gut microbiota and inflammatory bowel disease: an update.

Gut microbiota and inflammatory bowel disease: an update. Minerva Gastroenterol Dietol. 2017 Mar 14;: Authors: Holleran G, Lopetuso LR, Ianiro G, Pecere S, Pizzoferrato M, Petito V, Graziani C, Mc Namara D, Gasbarrini A, Scaldaferri F Abstract Major advances have occurred in the knowledge of the pathogenesis of Inflammatory Bowel Disease (IBD) over the last decade, and perhaps the most major, and clinically advantageous of these advances has been the discovery of the microbiome as a key multifaceted component of inflammation. The Gut microbiome is the largest known group of cells in the body, and is now recognised as an organ in its own right. Initial studies looking at a possible role of bacterial manipulation of the immune system in IBD, looked at identifying a specific bacterial species, and were not representative of a feasible model of inflammation in IBD overall. More recently there has been a shift towards the concept of dysbiosis, and the acceptance that a number of bacterial factors interact with the immune system in order for inflammation to occur. In the present review we will focus on past perspective of the role of microbiota in IBD, current evidences about dysbiosis in IBD and also the main therapeutic modalities to affect IBD by affecting gut microbiota: probiotics, prebiotics, faecal Microbiota Transplantation and emerging dietary intervention. PMID: 28293937 [PubMed - as supplied by publisher]
Source: Minerva Gastroenterologica e Dietologica - Category: Gastroenterology Tags: Minerva Gastroenterol Dietol Source Type: research